This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In this episode, Ayesha discusses a new tool that uses CRISPR to modulate geneexpression without editing DNA sequences. Dubbed “CRISPRoff,” the technology targets the epigenome to silence genes involved in diseases, with applications in cancer, AML and other conditions with a heritable component.
These modifications regulate geneexpression without changing the sequence or structure of DNA. Related: 2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the LifeSciences. We can do this for multiple genes at the same time without any DNA damage, and in a way that can be reversed.
These modifications regulate geneexpression without altering the sequence or structure of DNA. Related: 2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the LifeSciences. We can do this for multiple genes at the same time without any DNA damage, and in a way that can be reversed.
After several such Nobel Prize snubs for female scientists, 2020 saw the Nobel Prize in Chemistry go to a female scientist duo for the first time for their revolutionary discovery of the CRISPR-Cas9 geneediting system. As a Black female scientist, her legacy is one that will continue to inspire generations of Black women to come.
This difference could be mitigated when the scientists used a geneediting technique to either reduce KDM6A protein levels in the female-derived neurons, or increase KDM6A levels in neurons from males. Increasing KDM6A expression in male mice led them to be more resilient to the effects of amyloid beta plaques. KDM6A Variant.
The pandemic propelled the lifescience and healthcare sectors onto center stage, and they rose to the occasion against the most unprecedented health challenge in recent times. While COVID-19 has undoubtedly been the biggest story in the lifescience industry in 2020, it was a busy and positive year in many other areas.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content